Tag: Merck

Merck to Acquire Acceleron Pharma Inc.

Financial by 0 comments

Acquisition Complements and Strengthens Merck’s Cardiovascular Pipeline Sotatercept is a Potentially First-In-Class Therapy in Phase 3 Development for the Treatment of Pulmonary Arterial Hypertension REBLOZYL® (luspatercept-aamt) is a First-In-Class Erythroid Maturation Recombinant Fusion Protein Approved for the Treatment of Anemia in […]

Continue Reading →

NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases

Coronary/Structural Heart by 0 comments

Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and cardiovascular and metabolic (CVM) targets of interest to Merck Merck will continue to advance MK-3655, an FGFR1c/KLB agonistic antibody, currently […]

Continue Reading →

Janssen Submits Supplemental NDA to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients With Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)

Coronary/Structural Heart Peripheral/Endo by 0 comments

RARITAN, N.J., Dec. 11, 2017 /PRNewswire/ — Janssen Research & Development today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new XARELTO® (rivaroxaban) vascular indications: reducing the risk of major cardiovascular […]

Continue Reading →
1 2